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Background: Prostate smooth muscle tone is regulated by α1-adrenoceptor-induced contraction and
cAMP-mediated relaxation. EPAC is an effector of cAMP, being involved in smooth muscle relaxation and cell cycle
control outside the lower urinary tract. Here, we investigated the expression and function of EPAC in human
prostate tissues from patients undergoing radical prostatectomy.
Results: mRNA and protein expression of EPAC was detected in all prostate tissues by RT-PCR and Western blot
analysis. Immunoreactivity was observed in stromal cells, and colocalized with immunofluorescence for α-smooth
muscle actin and calponin. Under normal conditions, noradrenaline- or phenylephrine-induced contraction of
prostate strips in the organ bath was not affected by the EPAC activator pCPT (SP-8-pCPT-20-O-Me-cAMPS.NA)
(30 μM). However, when the cyclooxygenase inhibitor indomethacin (50 μM) was added, EPAC activators pCPT and
OME (8-CPT-20-O-Me-cAMP.Na) (30 μM) significantly reduced contractions by low concentrations of phenylephrine.
These effects were not observed on noradrenaline-induced contraction. OME and pCPT caused phosphorylation of
the transcription factor Elk1 in prostate tissues. Elk1 activation was confirmed by EMSA (electrophoretic mobility
shift assay), where OME and pCPT incresed Elk1 binding to a specific DNA probe.
Conclusions: EPAC activation may reduce α1-adrenergic prostate contraction in the human prostate, although this
effect is masked by cyclooxygenases and β-adrenoceptors. A main EPAC function in the human prostate may be
the regulation of the transcription factor Elk1.
Keywords: α1-adrenoceptor, Smooth muscle contraction, Smooth muscle relaxation, Cyclic adenosin-30,50-
monophosphate, EPAC, Elk1, Benign prostate hyperplasia (BPH), Benign prostate obstruction (BPO), Bladder outlet
obstruction (BOO), Lower urinary tract symptoms (LUTS)Background
Cyclic adenosine-3′,5′-monophosphate (cAMP) medi-
ates smooth muscle relaxation in the prostate and other
organs [1-3]. Prostate smooth muscle tone depends
on β-adrenoceptor/cAMP-mediated relaxation and α1-
adrenoceptor-induced contraction, besides other mecha-
nisms [4-6]. In patients with benign prostate syndrom
(BPS), enhanced prostate smooth muscle tone and pros-
tate enlargement may cause lower urinary tract symp-
toms (LUTS) [7-9]. Prostate tone and growth may be
targeted by treatment with α1-blockers and 5α-reductase* Correspondence: christian.gratzke@med.uni-muenchen.de
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distribution, and reproduction in any mediuminhibitors, which are important therapeutic options for
medical treatment of LUTS in patients with BPS [10].
Due to the high incidence of BPS and LUTS, together
with the importance of smooth muscle contraction for
therapy, the function of the adrenergic system in the
prostate and its pharmacologic modulation are of high
interest [10].
cAMP is produced by adenylyl cyclases, upon stimula-
tion of β-adrenoceptors or with cyclooxygenase-derived
prostaglandins [11,12]. After its formation, cAMP activates
protein kinase A (PKA) to induce relaxation, but causes
parallel interventions into gene transcription [1]. Alterna-
tively to PKA activation, cAMP may activate “exchangentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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EPACs represent a group of cAMP effectors, which medi-
ate cAMP effects independently from PKA [11,13]. Both
isoforms, EPAC1 and EPAC2 were recently described from
different cell types and organs, including smooth muscle
outside the lower urinary tract [11,13-16]. Motoric effects
of EPACs in smooth muscle have been regarded just re-
cently, using EPAC-specific activators [16]. Activation of
EPACs by these activators caused relaxation of airway
smooth muscle [16]. Besides these motoric effects, EPAC
activation by cAMP or specific activators results in activa-
tion of different transcription factors [17], which is involved
in EPAC-mediated regulation of cell cycle [11,13,17]. Previ-
ous studies suggested that Elk1 may be activated by cAMP-
dependent mechanisms in different organs and cell types
[18-23]. Of note, EPAC and cAMP-dependent Elk1 activa-
tion are involved in hyperplastic alterations outside the
lower urinary tract [13,18,19,24,25]. Although hyperlasia is
of utmost importance for BPS, EPAC-driven Elk1 activation
has not been investigated in the prostate.
Prostate smooth muscle tone is balanced by cAMP-
mediated relaxation and α1-adrenergic contraction, while
prostate growth requires the activation of transcription fac-
tors [24]. Prostate growth depends on the concerted inter-
action between growth factors, hormones and G protein-
coupled receptors, although little is known about their
intracellular mediators [26,27]. Prostate growth and con-
traction were regarded as separate phenomenons for de-
cades (“dynamic” and “static” component) [9]. However, it
has been recently postulated that both components may be
coupled to each other, although detailed mechanisms still
remain an enigma [4,8,28].
In the lower urinary tract, expression and function of
EPACs has not been investigated to date. Here, we inves-
tigated the expression of EPAC1 and EPAC2 in the hu-
man prostate, and studied the effects of EPAC activators
on adrenergic prostate contraction and on the transcrip-
tion factor Elk1.Methods
Human prostate tissue
Human prostate tissues were obtained from patients under-
going radical prostatectomy for prostate cancer, but without
previous transurethral resection of the prostate (TURP)
(n=61). The research was carried out in accordance with
the Declaration of Helsinki of the World Medical Associ-
ation, and has been approved by the ethics committee of
the Ludwig-Maximilians University, Munich, Germany. In-
formed consent was obtained from each patient. All samples
were taken from the periurethral zone, and analyzed an-
onymously. These tissue samples did not exhibit histological
signs of neoplasia, cancer, or inflammation. Most prostate
tumors are located to the peripheral zone [29,30].Sampling and in vitro stimulation
For analysis of EPAC expression, samples of prostate tissue
were shock frozen in liquid nitrogen directly after prosta-
tectomy and pathological examination. For myographic
measurements of contractility, tissues were handled as de-
scribed below. For in vitro stimulation with EPAC activa-
tors, prostate tissue specimens were prepared as small
strips (2–3 mm × 1 mm) and allocated to three dishes of a
6-well plate containing Custodiol solution. During the ex-
periments, plates were kept at 37°C under continous shak-
ing. For stimulation with EPAC activators, 10 mM stock
solutions were added in the required intervals and volumes
to obtain a final concentration of 30 μM pCPT or OME,
while another sample remained unstimulated. After 2 h,
stimulated and unstimulated samples were simultaneously
shock frozen in liquid nitrogen. Samples were stored
at −80°C until Western blot analysis was performed.
Quantitative RT-PCR
RNA from frozen prostate tissues was isolated using the
RNeasy Mini kit (Qiagen, Hilden, Germany). For isolation,
30 mg of tissue was homogenized using the FastPrep®-24
system with matrix A (MP Biomedicals, Illkirch, France).
RNA concentrations were measured spectrophotometric-
ally. Reverse transcription to cDNA was performed with 1
μg of isolated RNA using the Reverse Transcription System
(Promega, Madison, WI, USA). RT-PCR for EPAC1 and
EPAC 2 was performed with a Roche Light Cycler (Roche,
Basel, Switzerland) using primers provided by SA Biosci-
ences (Frederick, MD, USA) as ready-to-use mixes, based
on the RefSeq Accession numbers NM_006105 for EPAC1
(human RAPGEF3), and NM_007023 for EPAC2 (human
RAPGEF4). PCR reactions were performed in a volume of
25 μl containing 5 μl LightCycler® FastStart DNA
MasterPlus SYBR Green I (Roche, Basel, Switzerland), 1 μl
template, 1 μl primer, and 18 μl water. Denaturation was
performed for 10 min at 95°C, and amplification with 45
cycles of 15 sec at 95°C followed by 60 sec at 60°C. The
specificity of primers and amplification was demonstrated
by subsequent analysis of melting points, which revealed
single peaks for each target. The results were expressed as
the number of cycles (Ct), at which the fluorescence signal
exceeded a defined treshold.
Western blot analysis
Frozen prostate tissues were homogenized in a buffer
containing 25 mM Tris/HCl, 10 μM phenylmethanesulfonyl
fluoride, 1 mM benzamidine, and 10 μg/ml leupeptine
hemisulfate, using the FastPrep®-24 system with matrix A
(MP Biomedicals, Illkirch, France). After brief centrifuga-
tion, supernatants were assayed for protein concentration
using the Dc-Assay kit (Biorad, Munich, Germany) and
boiled for 10 min with sodium dodecyl sulfate (SDS) sample
buffer (Roth, Karlsruhe, Germany). Western blot analyses of
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detection, mouse anti EPAC1 (5D3) antibody, mouse anti
EPAC2 (5B1) antibody (both from New England Biolabs,
Ipswich, MA, USA), mouse anti phospho-Elk1 (serine 383)
antibody (B-4), mouse anti Elk1 antibody (3H6D12), mouse
anti pan-cytokeratin antibody (C11), mouse anti prostate
specific antigen (PSA) antibody (A67-B/E3), or mouse anti
β-actin antibody (all from Santa Cruz Biotechnology, Santa
Cruz, CA, USA) were used. Blots were developed with
enhanced chemiluminescence (ECL) using ECL Hyperfilm
(GE Healthcare, Freiburg, Germany). Intensities of
the resulting bands were quantified using Image J (NIH,
Bethesda, Maryland, USA). In stimulation experiments
with EPAC activators, samples without and with activator
were compared on one blot, and subjected to semiquanti-
tative quantification. For quantification, samples without
activator were set to 100%, and data of stimulated samples
from the same prostate were expressed as % of these un-
stimulated samples.
Immunohistochemistry
Sections (6–8 μm) from frozen tissues were stained by an
indirect immunoperoxidase technique, as previously de-
scribed [31]. For detection of EPAC1 and EPAC2, mouse
anti EPAC1 antibody (5D3) or EPAC2 antibody (5B1) (New
England Biolabs, Ipswich, MA, USA) were used in dilutions
of 1:200. Biotinylated secondary horse anti mouse anti-
body (Vector Laboratories, Burlingame, CA, USA) and
avidin-biotin-peroxidase complex (Vector Laborator-
ies, Burlingame, CA, USA) were sequentially applied for
30 minutes each. Staining was performed with the AEC
peroxidase substrate kit (Vector Laboratories, Burlingame,
CA, USA). Finally, all sections were counterstained with
hemalaun. Control stainings without primary antibodies
did not yield any immunoreactivity.
Immunofluorescence
Human prostate specimens, embedded in optimal cutting
temperature compound, were snap-frozen in liquid nitro-
gen and kept at −80°C. Sections (8 μm) were cut in a cryo-
stat and collected on microscope slides (Superfrost®).
Fluorescence stainings were performed as previously de-
scribed [31], using the following primary antibodies (di-
luted 1:50): mouse anti EPAC1 (5D3), mouse anti EPAC2
(5B1) (both from New England Biolabs, Ipswich, MA,
USA), rabbit anti EPAC1 (EPR1672) (Thermo Scientific,
Kalamazoo, MI, USA), mouse anti Elk1 (3H6D12) (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti
α-smooth muscle actin (αSMA) (RB-9010-P) (Thermo
Scientific, Kalamazoo, MI, USA), and rabbit anti calponin
(FL-297) (Santa Cruz Biotechnology, Santa Cruz, CA,
USA). Binding sites were visualized using Cy3 and Cy5
conjugated secondary antibodies (goat anti mouse,
AP124C, Millipore, Billerica, MA, USA, 1:1000; goat antirabbit, 1:1000, ab6564, Abcam, Cambridge, UK). Nuclei
were counterstained with DAPI (1:50,000, D1306,
Invitrogen, Camarillo, CA, USA) during incubation with
the secondary antibody. Immunolabelled sections were
analysed using a laser scanning microscope (Leica SP2,
Wetzlar, Germany). Control stainings without primary
antibodies did not yield any signals.
Tension measurements
Prostate strips (6×3×3 mm) were mounted in 5 ml aerated
(95% O2 and 5% CO2) tissue baths (Danish Myotechnology,
Aarhus, Denmark), containing Krebs-Henseleit solution
(37°C, pH 7.4). Preparations were stretched to 0.5 g and left
to equilibrate for 45 min to attain a stable resting tone. After
the equilibration period, maximum contraction induced by
80 mM KCl was assessed. Subsequently, chambers were
washed three times with Krebs-Henseleit solution for a total
of 30 min. Cumulative concentraction response curves for
noradrenaline or for the α1-adrenergic agonist phenyleph-
rine were created before and after addition of EPAC activa-
tors (30 μM pCPT, or 30 μM OME). In experiments
including indomethacin, this was added already during the
equilibration period, and applied throughout the entire
experiment.
EMSA
Activation of Elk1 was investigated by non-radioactive elec-
trophoretic mobility shift assay (EMSA). In this assay, the
binding of Elk1 to a biotin-labelled, Elk1-specific DNA
probe is determined. Assays were performed using a com-
mercially available kit (Affymetrix, Santa Clara, CA, USA)
according to the manufacturer’s instruction. In brief, pros-
tate tissues were homogenized as described forWestern blot
analysis, but not boiled with sample buffer. After protein de-
termination, 20 μg of protein were incubated with biotin-
labelled DNA probe with the sequence 5′TTTGCAAA
ATGCAGGAATTGTTTTCACAGT′3. After incubation,
samples were subjected to electrophoresis in native, non-
denaturating acrylamide gels (6%), and subsequently blotted
on nylon membranes, where detection for biotin was
performed with peroxidase-coupled streptavidin in combin-
ation with ECL. Intensities of the resulting bands were
quantified using Image J (NIH, Bethesda, Maryland, USA).
Experimental conditions were approved by preparation of a
negative control using an unlabelled probe provided by the
manufacturer. This cold probe was added to a sample be-




monophosphate sodium salt (“OME”) (Axxora, San Diego,
CA, USA) and 8-(4-chlorophenylthio)-2′-O-methylade
nosine-3′,5′-cyclic monophosphorothiorate SP-isomer
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unselective activators of EPAC [32,33]. Both were dissolved
in water and kept as 10 mM stock solutions at −20°C until
use. Aqueous stock solutions for noradrenaline and of the
α1-adrenoceptor agonist phenylephrine (Sigma, St. Louis,
MO, USA) (10 mM) were freshly prepared for each
experiment.
Statistical analysis
Data are presented as means ± standard error of the mean
(SEM) with the indicated number (n) of experiments. Two-
tailed student t test was used for paired or unpaired observa-
tions. P values <0.05 were considered statistically significant.Figure 1 EPAC expression in the human prostate. mRNA (A) and prote
(A), mRNA expression was investigated by quantitative RT-PCR in prostate
expression of EPAC1, EPAC2, pan-cytokeratin, PSA, and β-actin was investigResults
Quantitative RT-PCR
Expression of EPAC1 and EPAC2 mRNA was detected in
prostate samples from all investigated patients (n=5). Aver-
age Ct was 26 ± 0.3 for EPAC1, and 25 ± 0.2 for EPAC2,
while the housekeeping gene 18SrRNA was detectable with
an average Ct of 11 ± 0.2 (Figure 1A).
Western blot analysis of EPAC expression
Western blot analysis using isoform-specific EPAC anti-
bodies demonstrated variable protein expression of EPAC1
and EPAC2 in prostate tissues of all investigated patients
(n=5). Detected bands matched the expected sizes for bothin (B) expression of EPAC 1 and EPAC2 in human prostate tissues. In
tissues from n=5 patients (data are means ± SEM). In (B), protein
ated by Western blot analyses in prostate tissues from n=5 patients.
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(Figure 1B). The intensity of bands for EPAC1 and EPAC
varied between different patients (Figure 1B). The content
of epithelial markers, pan-cytokeratin (37–55 kDa) and
PSA (30 kDa) varied between prostates of different patients
(Figure 1B). The content of β-actin was similar in samples
of different patients (Figure 1B).Double fluorescence staining
Fluorescence staining of prostate sections resulted in
immunoreactivity for EPAC1 and EPAC2, and for the
smooth muscle markers α-smooth muscle actin (αSMA)
and calponin in prostate tissues from all investigated
patients (n=5) (Figure 2). Virtually all αSMA- and
calponin-positive cells were immunoreactive for EPAC1
and EPAC2 (Figure 2). This colocalization was indicated
by yellow color in merged pictures after overlay. No im-
munoreactivities were observed in control experiments,
where the primary antibodies were replaced by PBS.Figure 2 Double fluorescence stainings of human prostate sections fo
or calponin. Stainings were performed using isoform-specific EPAC antibo
resulted in yellow color in merged pictures after overlay. Shown are repres
with similar results.After double labelling for EPAC1 and EPAC2, immunore-
activity for EPAC1 was strongest in epithelial cells, but also
observed in the stroma (Figure 3). In contrast, immunoreac-
tivity for EPAC2 was strong in the stroma, but almost absent
in epithelial cells (Figure 3). Colocalization of EPAC1 and
EPAC2 was not observed (Figure 3). After double label-
ling for Elk1 and calponin, immunoreactivity for Elk1
was observed in the stroma (Figure 3). In epithelial
cells, almost no Elk1 immunoreactivity was observed
(Figure 3). In merged pictures, yellow color indicating
colocalization of Elk1 and calponin was weak, but de-
tectable (Figure 3).Immunohistochemical staining
Immunohistochemical staining of prostate sections using
EPAC1 and EPAC2 antibodies resulted in immuno-
reactivites in stromal cells (n=5 patients) (Figure 4). In con-
trol experiments, where antibodies were replaced by PBS,
no immunoreactivities were observed (Figure 4).r EPAC1 or EPAC2, and α-smooth muscle actin (αSMA)
dies. Colocalization of EPAC with αSMA- or calponin-positive cells
entative stainings from experiments with tissues from n=5 patients
Figure 3 Double fluorescence stainings of human prostate sections for EPAC1 and EPAC2 (left), or for Elk1 and calponin (right).
Colocalization resulted in yellow color in merged pictures after overlay, which is slightly visible after double labelling for Elk1 and calponin.
Shown are representative stainings from experiments with tissues from n=5 patients with similar results.
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In myographic measurements, phenylephrine and nor-
adrenaline induced concentration-dependent contractions
of isolated prostate strips. Under normal conditions, pCPT
(30 μM) was without effects on phenylephrine-induced
contractions (Figure 5A). When the cyclooxygenase inhibi-
tor indomethacin (50 μM) was added before constructionFigure 4 Immunohistochemical stainings of human prostate sections
were performed using an EPAC1 antibody in (A), or an EPAC2 antibody in
primary antibodies were replaced by phosphate-buffered saline (PBS). Show
patients in (A) and (B).of concentration response curves, pCPT significantly
reduced contraction by 3 μM phenylephrine (p<0.05)
(Figure 5B). Similarly, OME (30 μM) significantly reduced
contractions by 3 μM (p<0.02) and 10 μM phenylephrine
(p<0.02), when indomethacin was added (Figure 5C).
In contrast, pCPT was without effects on noradrenaline-
induced contractions, regardless whether indomethacinwith isoform-specific EPAC antibodies. Peroxidase-based stainings
(B). Immunoreactivity resulted in brown color. In control stainings,
n are representative stainings from series with prostates from n= 5
Figure 5 Effects of pCPT and OME on phenylephrine-induced contraction of human prostate strips. Phenylephrine-induced contraction
was measured before and after application of pCPT, OME, or water (solvent). In (B) and (C), the inhibitor of cyclooxyenases, indomethacin (50 μM)
was added during the entire experiment. Data are means ± SEM from experiments with prostates from n=2 patients in (A), n=7 patients in (B),
and n=8 patients in (C) (* p<0.05 vs. pCPT, ** p<0.02 vs. OME).
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out effect on noradrenaline-induced contractions in the
presence of indomethacin (Figure 6C).
Western blot analysis of Elk1 phosphorylation
Using a phospho-specific antibody, the effect of OME and
pCPT on Elk1 phosphorylation was determined byWestern blot analysis. Incubation of prostate tissues with
OME or pCPT for 2 h significantly increased the phos-
phorylation state of Elk1. After incubation with OME
(30 μM), Elk1 phosphorylation was 276 ± 33% of unstimu-
lated controls (p<0.0004) (Figure 7). After incubation with
pCPT (30 μM), Elk1 phosphorylation was 370 ± 56% of un-
stimulated controls (p<0.0007) (Figure 7). The content of
Figure 6 Effects of pCPT and OME on noradrenaline-induced contraction of human prostate strips. Noradrenaline-induced contraction was
measured before and after application of pCPT, OME, or water (solvent). In (B) and (C), the inhibitor of cyclooxyenases, indomethacin (50 μM) was added
during the entire experiment. Data are means ± SEM from experiments with prostates from n=6 patients in (A), n=7 patients in (B), and n=5 patients in (C).
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stimulated and unstimulated samples in each experiment
(Figure 7).
EMSA
Using an electrophoretic mobility shift assay (EMSA),
we investigated Elk1 activation by EPAC activators. In
this assay, the binding of Elk1 to the DNA sequence 5′TTTGCAAAATGCAGGAATTGTTTTCACAGT′3 is
assessed. Incubation of prostate tissues (n=5 patients)
with pCPT or OME (30 μM, 2 h) resulted in binding of
Elk1 to this sequence (Figure 8). DNA binding after in-
cubation with pCPT was 264 ± 62% of the binding in
unstimulated samples (p<0.04). Similarly, DNA binding
after incubation with OME was 375 ± 110% of the bind-
ing in unstimulated samples (p<0.04).
Figure 7 Effects of OME and pCPT on the content of phospho-Elk1 in human prostate tissue. Samples from one prostate were incubated
for 2 h with OME (30 μM), pCPT (30 μM), or water (solvent), and subsequently analyzed for phospho-Elk1, total Elk1, pan-cytokeratin, PSA, and
β-actin by Western blot analysis. Shown are representative Western blots in (A), and densitometric quantification in (B) from experiments with
prostates from n=6 (phospho-Elk) patients (* p<0.0007 vs. H2O).
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In the prostate and other organs, cyclic adenosine-3′,5′-
monophosphate (cAMP) is a second messenger mediating
smooth muscle relaxation [1]. In addition to its role for
smooth muscle tone, cAMP is involved in non-motoric
functions, including regulation of gene transcription or cell
cycle in many cell types and organs [17,24,25]. cAMP-
dependent effects may be mediated either by PKA, or by
EPAC [11,13]. By PKA and EPAC, cAMP may be assorted
to different intracellular compartments, and consequently
to divergent cellular functions [11,13]. In smooth muscle
outside the lower urinary tract, cAMP-dependent EPAC
activation mediates relaxation and regulates cell cycle, be-
sides its involvement in other functions [14-16]. Smooth
muscle tone and growth are important factors contributing
to the pathophysiology and therapy of LUTS in patients
with BPS [7-10]. To the best of knowledge, the expression
and function of EPAC in the prostate has not been investi-
gated to date. Here, we studied EPAC expression andEPAC functions in human prostate smooth muscle, using
EPAC-specific activators.
Using RT-PCR, Western blot analysis, and immunohis-
tochemistry, we observed expression of EPAC1 and EPAC2
in prostate samples from all investigated patients. In West-
ern blot analysis, EPAC expression levels varied together
with the epithelial markers, PSA and pan-cytokeratin be-
tween prostates of different patients. Despite these varia-
tions, EPAC was detectable in all samples, indicating that a
constitutive expression exists. Nevertheless, our analyses
demonstrate that EPAC expression underlies regulation.
The different content of epithelial markers may reflect dif-
ferent degrees of prostate hyperplasia. In fact, almost all
patients undergoing radical prostatectomy show hyper-
plastic prostates, although to different extent [34,35].
Therefore, we assume that our findings reflect the situation
in hyperplastic tissue, where the expression level of EPAC
may vary with the degree of hyperplasia. A comparison to
non-hyperplastic tissues was not possible, as these tissues
Figure 8 Elk1 activation by OME and pCPT in human prostate tissue. Samples from one prostate were incubated for 2 h with OME (30 μM),
pCPT (30 μM), or water (solvent), and subsequently analyzed by an Elk1-specific EMSA. Binding of Elk1 to the specific, biotin-labelled DNA probe
causes a shift in migration during electrophoresis, as indicated in (A). Experimental conditions were approved by preparation of a negative
control using an unlabelled probe, which was added to a sample besides the labelled probe, resulting in competition and disappearence of
bands. Shown is a representative experiment in (A), and densitometric quantification in (B) from experiments with prostates from n=5 patients
(* p<0.04 vs. H2O).
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demonstrate a new principle of EPAC signaling in non-
malignant prostate tissue, independent of pathophysio-
logical context. Immunoreactivity for EPAC1 and EPAC2
was located to stromal cells. To confirm that these cells are
smooth muscle cells, we performed double immunofluor-
escence stainings of prostate sections. Indeed, immunore-
activity for both EPAC isoforms colocalized with αSMA,
which is a common marker for smooth muscle cells.
Recently, different cell-permeable EPAC activators have
been developed, which are indispensable tools forinvestigations of EPAC functions [32,33]. These activators,
are analogs of cAMP, which do not activate PKA, but are
resistant to hydrolysis by phosphodiesterases [32,33]. Al-
though OME and pCPT are specific activators of EPAC,
they do not discriminate between EPAC1 and EPAC2. In
our organ bath experiments, activation of EPAC caused in-
hibition by low concentrations of phenylephrine, when cy-
clooxygenase activity was blocked by indomethacin. In
experiments, where indomethacin was omitted or contrac-
tion was induced by noradrenaline, EPAC activation was
without effects on contraction. In contrast to noradrenaline,
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lectively activates α1-adrenoceptors. Of note, these effects
were confirmed using two different EPAC activators, OME
and pCPT. In conclusion, a contribution of EPAC to pros-
tate smooth muscle tone may exist, althouth to minor
extent. Cyclooxygenases and noradrenaline-induced β-
adrenoceptor activation cause cAMP production [11,12].
Under physiologic conditions, this may raise EPAC activity
to a level, where further EPAC activation by OME or pCPT
is in ineffective on prostate smooth muscle tone. When
this background of cAMP was deleted in our experiments
(by indomethacin and selective activation of α1-
adrenoceptors), the effect of EPAC activators on contrac-
tion became visible.
Relaxation in response to EPAC activators has been re-
cently described from airway smooth muscle, where
EPAC-mediated relaxation may exceed the effects in the
prostate [16]. We assume that any difference to our study
may be either explained by the divergent, organ-specific
contractile systems in both organs, or by a tissue-specific
equipment with different molecular EPAC effectors.
Whether EPAC has a role in other smooth muscle types of
the lower urinary tract, in particular within the bladder,
may be subject of further studies.
Regulation of gene transcription by cAMP has been
known since decades [17,36]. By interventions into tran-
scriptional activity, cAMP is involved in various central
functions, including cellular growth, differentiation and
regulation of cell cycle [32,36]. In fact, different tran-
scription factors were identified, which may be activated
by cAMP and EPAC [17]. Although the focus of previ-
ous studies was on the regulation of CREB by cAMP,
several studies suggested that cAMP activates Elk1 in
different organs and cell types [18-23]. Therefore, we in-
vestigated whether EPAC activators may trigger Elk1 ac-
tivation in the prostate. We observed that stimulation of
human prostate tissues with EPAC activators results in
activation of Elk1.
Elk1 is activated by a phosphorylation, resulting in bind-
ing of the factor to a specific DNA sequence within the
promoter region of target genes [37,38]. Activation of Elk1
in our samples was confirmed by Western blot analysis
using a phospho-specific antibody, and by EMSA, where
the binding of transcription factors to a specific, biotin-
labelled DNA probe is assessed. Among different functions
of Elk1, Elk1-dependent proliferation, growth and differen-
tiation have been described from smooth muscle cells and
other cell types [38-41]. In the liver, cAMP-mediated Elk1
activation mediates hyperplasia of bile ducts [18,19]. In
prostate cancer cells, Elk1 is involved in proliferation and
tumor growth [42,43]. To the best of our knowledge, our
study suggesting a link between EPAC and Elk1 activation
is the first regarding Elk1 in non-malignant prostate cells,
or linking EPAC to Elk1 activation in any cell type. Elk1-specific inhibitors, which may enable detailed studies on
Elk1 function, have not been developed to date. We as-
sume that EPAC uses different effectors besides Elk1 in the
prostate. However, a role for Elk1 in the control of smooth
muscle tone appears unlikely. Future studies may focus on
the identification of Elk1 target genes in the prostate.
Non-motoric EPAC functions were studied in a panel of
cell types, including smooth muscle cells outside the lower
urinary tract. In airway smooth muscle cells, EPAC regu-
lates the phenotype of smooth muscle cells, and inhibited
growth factor-induced proliferation [14,15]. Apart from
smooth muscle cells, the role of EPAC was studied in
different cell types, with diverging results. In prostate
carcinoma cells, an antiproliferative effect as well as EPAC-
driven proliferation was observed [44,45]. EPAC triggers
proliferation in endothelial cells, macrophages, thyroid
cells, or osteoblasts, [46-49]. Indeed, the opposing charac-
ter of EPAC functions, in particular with regard to cell
cycle regulation already attracted attention [32]. Interest-
ingly, EPAC functions are often associated with the same
biological processes, despite opposing effects [11].
Together, EPAC-specific activators induce activation of
the transcription factor Elk1 in the human prostate. In
contrast, EPAC-mediated relaxation of prostate smooth
muscle may be at best minor. Nevertheless, cAMP is an
important mediator causing prostate smooth muscle re-
laxation by PKA [1]. This may suggest possible connec-
tions between smooth muscle tone and growth in the
prostate. Although such links have been proposed by
various investigators, little is known about their intracel-
lular mediators [4,8,26-28]. In cardiomyocytes, EPAC ac-
tivation causes hypertrophic responses, by intervention
into transcription of hypertrophic genes [13,24,25]. In
conclusion, a role of EPAC in prostate hyperplasia may
be postulated.
Conclusions
Our findings point to a role of EPAC in transcriptional regu-
lation in smooth muscle cells of the human prostate. EPAC-
dependent regulation of prostate smooth muscle tone may
be masked by cyclooxygenases and β-adrenoceptors. To-
gether, EPAC may represent a missing link connecting the
dynamic with the static component in BPH.Abbreviations
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